CareDx introduced AlloSeq Nano at the European Federation for Immunogenetics (EFI) Conference 2026, unveiling a nanopore‑based platform that delivers high‑resolution HLA and ABO blood‑type genotyping.
AlloSeq Nano offers a 45‑minute hands‑on sample preparation time and completes genotyping in under three hours, leveraging long‑read sequencing to reduce phasing ambiguities and improve accuracy for transplant matching.
The launch expands CareDx’s HLA typing portfolio beyond its current next‑generation sequencing (NGS) products, positioning the company to capture a larger share of the transplant diagnostics market and creating cross‑sell opportunities with its AlloSure and AlloMap services.
In parallel, CareDx has agreed to divest its Lab Products business to EuroBio Scientific for $170 million, a transaction expected to close in the third quarter of 2026. The divestiture allows CareDx to focus on its core testing services and digital solutions, which have shown stronger growth.
Financially, CareDx reported Q4 2025 revenue of $108.4 million, up 25% year‑over‑year, and preliminary Q1 2026 revenue of $118 million, up 39% year‑over‑year. The company’s 2026 revenue guidance ranges from $420 million to $444 million, reflecting continued momentum in its core segments.
AlloSeq Nano represents a significant operational milestone that enhances CareDx’s ability to serve centers requiring rapid, accurate donor‑recipient compatibility decisions, reinforcing its competitive moat in the transplant diagnostics market and supporting the broader precision‑medicine strategy.
The product launch is expected to add a new revenue stream and strengthen CareDx’s market position, aligning with the company’s focus on high‑growth testing services and digital solutions.
revised_sentiment_rating":3} }
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.